المؤلفون: Pavla Koralkova, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Pavla Vyhlidalova, Jan Stetka, Alzbeta Hlavackova, Jiri Suttnar, Patrik Flodr, Jan Stritesky, Anna Jonasova, Jaroslav Cermak, Vladimir Divoky

المصدر: Cancers, Vol 13, Iss 9, p 2161 (2021)

مصطلحات موضوعية: myelodysplastic syndromes, azacitidine therapy, metabolic signature, IDH2, histone acetylation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.mdpi.com/2072-6694/13/9/2161; https://doaj.org/toc/2072-6694

URL الوصول: https://doaj.org/article/9fe1fdc230ef40adabab7e4e7b5c758e

المؤلفون: Vladimir Divoky, Monika Belickova, Pavla Vyhlidalova, Jitka Vesela, Alzbeta Hlavackova, Jiri Suttnar, Monika Kaisrlikova, Katarina Szikszai, Anna Jonasova, Patrik Flodr, Zdenek Krejcik, Jan Stetka, Pavla Koralkova, David Kundrat, Jan Stritesky, Michaela Dostalova Merkerova, Jaroslav Cermak

المصدر: Cancers
Cancers, Vol 13, Iss 2161, p 2161 (2021)
Volume 13
Issue 9

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, metabolic signature, Azacitidine, IDH2, Article, 03 medical and health sciences, 0302 clinical medicine, azacitidine therapy, hemic and lymphatic diseases, medicine, Progenitor cell, RC254-282, biology, Myelodysplastic syndromes, histone acetylation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Myeloid leukemia, medicine.disease, myelodysplastic syndromes, Haematopoiesis, 030104 developmental biology, Isocitrate dehydrogenase, Histone, Oncology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4c2c750a01f8fbd3b1728307c2641fd
http://europepmc.org/articles/PMC8125503

المؤلفون: Peter J. M. Valk, Yves Chalandon, Thomas Pabst, Markus G. Manz, Dimitri Breems, Maaike Sohne, Bob Löwenberg, Emanuele Ammatuna, Marjolein van der Poel, Sabine Blum, Dries Deeren, Rien van Marwijk Kooy, Dana A. Chitu, Mojca Jongen-Lavrencic, Lidwine W. Tick, Marie Cecile J.C. Legdeur, Gerwin Huls, Saskia K. Klein, Danielle van Lammeren-Venema, Gert J. Ossenkoppele, Georg Stussi, Arjan A. van de Loosdrecht, Isabelle A van Zeventer, Rinske S. Boersma, M. Fehr, Mels Hoogendoorn, Jacqueline Cloos, Laimonas Griskevicius

المساهمون: Stem Cell Aging Leukemia and Lymphoma (SALL), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Hematology laboratory, CCA - Cancer Treatment and quality of life, Hematology, University of Zurich, Huls, Gerwin, Interne Geneeskunde, MUMC+: MA Hematologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

المصدر: Blood advances, vol. 4, no. 18, pp. 4267-4277
Blood Advances, Vol. 4, No 18 (2020) pp. 4267-4277
Blood, 4(18), 4267-4277. AMER SOC HEMATOLOGY
Blood, 4(18), 4267-4277. American Society of Hematology
Blood advances, 4(18), 4267-4277. American Society of Hematology
Huls, G, Chitu, D A, Pabst, T, Klein, S K, Stussi, G, Griskevicius, L, Valk, P J M, Cloos, J, van de Loosdrecht, A A, Breems, D, van Lammeren-Venema, D, van Zeventer, I, Boersma, R, Jongen-Lavrencic, M, Fehr, M, Hoogendoorn, M, Manz, M G, Söhne, M, Kooy, R V M, Deeren, D, van der Poel, M W M, Legdeur, M C, Tick, L, Chalandon, Y, Ammatuna, E, Blum, S, Löwenberg, B & Ossenkoppele, G J 2020, ' Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS ', Blood, vol. 4, no. 18, pp. 4267-4277 . https://doi.org/10.1182/BLOODADVANCES.2020002846
Blood advances, 4(18), 4267-4277. The American Society of Hematology
Blood Adv

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Clinical Trials and Observations, medicine.medical_treatment, 2720 Hematology, Decitabine, MINIMAL RESIDUAL DISEASE, 610 Medicine & health, Hematopoietic stem cell transplantation, ACUTE MYELOID-LEUKEMIA, chemistry.chemical_compound, Piperidines, Internal medicine, CONVENTIONAL CARE REGIMENS, AZACITIDINE THERAPY, Humans, Medicine, Adverse effect, TREATMENT RESPONSE, Netherlands, MYELODYSPLASTIC SYNDROME, ddc:616, business.industry, Adenine, CLINICAL-RESPONSE, Myeloid leukemia, Hematology, Minimal residual disease, Transplantation, Leukemia, Myeloid, Acute, chemistry, Tolerability, HYPOMETHYLATING AGENT THERAPY, Myelodysplastic Syndromes, Ibrutinib, 10032 Clinic for Oncology and Hematology, SURVIVAL, TRIAL, business, medicine.drug

وصف الملف: application/pdf; advancesadv2020002846.pdf - application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f035f8641df261cae7346abf960dbaaf
https://serval.unil.ch/notice/serval:BIB_BA95A00DDE07

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.